Asked to organize an international meeting on Propafenone (Ryt monorm) we had to question ourselves, whether to accept this offer just as interested physicians or in our capacity as chairmen of the study group on arrhythmias and intracardiac electrography of the European Society of Cardiology. Considerung the "pros and contras" and well aware that one can easily be regarded as "product promoter" we, nevertheless, choose to organize the Symposion in association with the study group. We felt justified to do so for a number of reasons: Arrhyth mias and their treatment as well as the tools to…mehr
Asked to organize an international meeting on Propafenone (Ryt monorm) we had to question ourselves, whether to accept this offer just as interested physicians or in our capacity as chairmen of the study group on arrhythmias and intracardiac electrography of the European Society of Cardiology. Considerung the "pros and contras" and well aware that one can easily be regarded as "product promoter" we, nevertheless, choose to organize the Symposion in association with the study group. We felt justified to do so for a number of reasons: Arrhyth mias and their treatment as well as the tools to detect the first and to control the latter are well within the scope of the study group. An international symposion provided the opportunity to have the "state of the art" in arrhythmias and antiarrhythmic treatment thoroughly reviewed by internationally renowned investigators, thus serving an educational purpose. Furthermore it was the intention and aim of the meeting to have what is known about a fairly new drug presented in a critical manner and to point out what is not known, but should be known. It is in that context the presentations of the free session should be judged. To the careful reader it will become apparent that much which was not said, can be read "between the lines".Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Table of Contens.- Differentiation Between "Normal" and "Abnormal" in Ambulatory Electrocardiography.- Identification of the Patient at High Risk of Sudden Cardiac Death.- Efficacy of Oral Propafenone in Supraventricular and Ventricular Arrhythmias: Experience with 47 Cases.- The Possible Relevance of Late Potentials for the Identification of Patients Needing Antiarrhythmic Treatment.- Simulation Studies for the Interpretation of Delayed Potentials.- Electrophysiologic Testing in Patients with Ventricular Tachycardia.- Results of Invasive Methods.- Specific Antiarrhythmic Drugs for Specific Arrhythmias.- Sudden Cardiac Death: Prognosis of Long-term Antiarrhythmic Therapy.- Basic Electrophysiological Actions of Propafenone in Heart Muscle.- The Pharmacology of Propafenone.- Clinical Pharmacology of Propafenone.- Pharmacokinetic and Metabolic Studies on Propafenone in Volunteers.- Effects of Propafenone on Hemodynamics and Cardiac Inotropy.- Interaction Between Propafenone and Other Drugs.- Comparison of the Efficacy of Propafenone and Lidocaine in Patients with Acute Myocardial Infarction and Ventricular Extrasystoles : Result of a 24-h Holter Monitoring.- Observations on the Antiarrhythmic Effects of Rytmonorm.- Comparative Study of the Therapeutic Effect of Propafenone and Disopyramide in the Oral Treatment of Chronic Ventricular Premature Beats.- Propafenone, Flecainide and Mexiletine in the Treatment of Stable Ventricular Premature Beats.- Long-term Prognosis for Patients with Complex Ventricular Arrhythmias of Lown Grades IVa and IVb.- Experience with Propafenone in the Treatment of Arrhythmias in Pediatric Patients.- Electrophysiologic Effects and Antiarrhythmic Efficacy of Rytmonorm Evaluated with Programmed Electrical Stimulation of the Heart in Patientswith Recurrent Reentrant Supraventricular Tachycardia.- Antiarrhythmic Effect and Study of Segmentary Contractility Following the Administration of Propafenone in Coronary Patients with Ventricular Arrhythmias.- Propafenone in Office Use: Results of an Open, Multicenter Study.- The Safety and Efficacy of Propafenone in Suppressing Ventricular Ectopy.- Dose-Response Effect of Propafenone in Patients with Ventricular Arrhythmias.- Treatment of Severe Ventricular Arrhythmias with Propafenone.- Use of Propafenone for the Prevention of Ventricular Hyperkinetic Arrhythmias in the Mitral Valve Prolapse Syndrome.
Table of Contens.- Differentiation Between "Normal" and "Abnormal" in Ambulatory Electrocardiography.- Identification of the Patient at High Risk of Sudden Cardiac Death.- Efficacy of Oral Propafenone in Supraventricular and Ventricular Arrhythmias: Experience with 47 Cases.- The Possible Relevance of Late Potentials for the Identification of Patients Needing Antiarrhythmic Treatment.- Simulation Studies for the Interpretation of Delayed Potentials.- Electrophysiologic Testing in Patients with Ventricular Tachycardia.- Results of Invasive Methods.- Specific Antiarrhythmic Drugs for Specific Arrhythmias.- Sudden Cardiac Death: Prognosis of Long-term Antiarrhythmic Therapy.- Basic Electrophysiological Actions of Propafenone in Heart Muscle.- The Pharmacology of Propafenone.- Clinical Pharmacology of Propafenone.- Pharmacokinetic and Metabolic Studies on Propafenone in Volunteers.- Effects of Propafenone on Hemodynamics and Cardiac Inotropy.- Interaction Between Propafenone and Other Drugs.- Comparison of the Efficacy of Propafenone and Lidocaine in Patients with Acute Myocardial Infarction and Ventricular Extrasystoles : Result of a 24-h Holter Monitoring.- Observations on the Antiarrhythmic Effects of Rytmonorm.- Comparative Study of the Therapeutic Effect of Propafenone and Disopyramide in the Oral Treatment of Chronic Ventricular Premature Beats.- Propafenone, Flecainide and Mexiletine in the Treatment of Stable Ventricular Premature Beats.- Long-term Prognosis for Patients with Complex Ventricular Arrhythmias of Lown Grades IVa and IVb.- Experience with Propafenone in the Treatment of Arrhythmias in Pediatric Patients.- Electrophysiologic Effects and Antiarrhythmic Efficacy of Rytmonorm Evaluated with Programmed Electrical Stimulation of the Heart in Patientswith Recurrent Reentrant Supraventricular Tachycardia.- Antiarrhythmic Effect and Study of Segmentary Contractility Following the Administration of Propafenone in Coronary Patients with Ventricular Arrhythmias.- Propafenone in Office Use: Results of an Open, Multicenter Study.- The Safety and Efficacy of Propafenone in Suppressing Ventricular Ectopy.- Dose-Response Effect of Propafenone in Patients with Ventricular Arrhythmias.- Treatment of Severe Ventricular Arrhythmias with Propafenone.- Use of Propafenone for the Prevention of Ventricular Hyperkinetic Arrhythmias in the Mitral Valve Prolapse Syndrome.
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
USt-IdNr: DE450055826